62921-36-2 Usage
Uses
Used in Pharmaceutical Industry:
(12Z,14E,24Z)-5,6,11,17,19-pentahydroxy-23-methoxy-2,4,9,12,16,18,20,22-octamethyl-1-oxo-1,2,9,10-tetrahydro-2,8-(epoxytetradeca[1,11,13]trieno)[1]benzofuro[4,5-g]quinazolin-21-yl acetate is used as a potential pharmaceutical agent due to its complex structure and the presence of multiple functional groups that may contribute to its biological activity. (12Z,14E,24Z)-5,6,11,17,19-pentahydroxy-23-methoxy-2,4,9,12,16,18,20,22-octamethyl-1-oxo-1,2,9,10-tetrahydro-2,8-(epoxytetradeca[1,11,13]trieno)[1]benzofuro[4,5-g]quinazolin-21-yl acetate's specific applications could include targeting various diseases or conditions based on its interaction with biological systems.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (12Z,14E,24Z)-5,6,11,17,19-pentahydroxy-23-methoxy-2,4,9,12,16,18,20,22-octamethyl-1-oxo-1,2,9,10-tetrahydro-2,8-(epoxytetradeca[1,11,13]trieno)[1]benzofuro[4,5-g]quinazolin-21-yl acetate serves as a subject of research for understanding its potential therapeutic effects. The intricate structure of the molecule, including the benzofuroquinazoline ring system and the epoxytetradeca[1,11,13]trieno substructure, makes it an interesting candidate for exploring new drug development pathways and mechanisms of action.
Check Digit Verification of cas no
The CAS Registry Mumber 62921-36-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,2,9,2 and 1 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 62921-36:
(7*6)+(6*2)+(5*9)+(4*2)+(3*1)+(2*3)+(1*6)=122
122 % 10 = 2
So 62921-36-2 is a valid CAS Registry Number.
62921-36-2Relevant academic research and scientific papers
3-N-substituted aminomethyl derivatives of rifamycin SV. A convenient method of synthesis, cyclization of certain derivatives, and anticellular and antiviral activities of several derivatives
McCarthy,Moore,Wysong,Aldrich
, p. 1272 - 1276 (2007/10/21)
A new synthesis of Mannich bases of rifamycin SV using the Borch procedure with rifaldehyde is described. This new synthesis offers two advantages over the previously published method. It provides a route to monoalkyl-aminomethylrifamycins (1e-h) and to unsubstituted aminomethylrifamycins that were not accessible by the old procedure. The new method also offers a preparative route to Mannich bases 1a and 1b which were needed in multigram quantities for biological testing. In addition, the cyclization of certain of the monoalkylaminomethylrifamycins to the novel N,15 didehydro 15 deoxo 3,15 epi[methano(alkylimino)]rifamycin SV derivatives is described. The anticellular and antiviral effects of representatives of both series of compounds against cultured mouse cells and murine oncornavirus are discussed.
